Immunocore Holdings Plc-adr (IMCR) 13F Holdings Overview (Q2 2026)

IMCR ranks #3945 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

IMCR is a top-conviction position for Trails Edge Capital Partners, LP — at 5.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in IMCR belongs to Wellington Management Group LLP, but the position matters far more to Trails Edge Capital Partners, LP, who has 5.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Two Sigma Investments, LP has added to its IMCR position for two straight quarters, increasing it by $39.9M to reach $52.4M today.

Deep Track Capital, LP has trimmed its IMCR position for two straight quarters, cutting it by $59.7M while still holding $9.9M.

IMCR is up 1.4% today, and institutions have been net buyers of $100.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

IMCR reported a net loss of $18.1M over the trailing twelve months.

• Not yet profitable — net loss of $18.1M over the trailing twelve months
• Revenue grew 21.0% year over year
• Net income improved year over year, from -$20.3M to -$18.1M
• Operating cash flow was negative, using $10.7M in cash
• Current ratio of 4.04x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.80x equity — within a conventional range